Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 12, 2022

Impaired Glucagon-Mediated Suppression of VLDL-TG Secretion in Individuals With MAFLD



Additional Info

Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Diabetes 2022 Nov 01;71(11)2402-2411, S Heebøll, J Risikesan, S Ringgaard, I Kumarathas, TD Sandahl, H Grønbæk, E Søndergaard, S Nielsen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading